Viral Vectors and Plasmid DNA Manufacturing - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB503246854

Publication Date:

March 13, 2024

Pages:

122

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.
The global market for Viral Vectors and Plasmid DNA Manufacturing was estimated to be worth US$ 608 million in 2023 and is forecast to a readjusted size of US$ 1961.9 million by 2030 with a CAGR of 18.0% during the forecast period 2024-2030
Global Viral Vectors and Plasmid DNA Manufacturing key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific, and Europe, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections , etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Viral Vectors and Plasmid DNA Manufacturing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Viral Vectors and Plasmid DNA Manufacturing by region & country, by Type, and by Application.
The Viral Vectors and Plasmid DNA Manufacturing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors and Plasmid DNA Manufacturing.
麻豆原创 Segmentation
By Company
BioReliance
Cobra Biologics
Oxford BioMedica
UniQure
FinVector
MolMed
MassBiologics
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Lonza
Aldevron
Eurogentec
Cell and Gene Therapy Catapult
Biovian
Thermo Fisher Scientific (Brammer Bio)
VGXI
PlasmidFactory
Segment by Type:
Plasmid DNA
Viral Vectors
Segment by Application
Cancers
Inherited Disorders
Viral Infections
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Viral Vectors and Plasmid DNA Manufacturing manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Viral Vectors and Plasmid DNA Manufacturing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Viral Vectors and Plasmid DNA Manufacturing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Viral Vectors and Plasmid DNA Manufacturing Product Introduction
1.2 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size Forecast
1.3 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Trends & Drivers
1.3.1 Viral Vectors and Plasmid DNA Manufacturing Industry Trends
1.3.2 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Drivers & Opportunity
1.3.3 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Challenges
1.3.4 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Viral Vectors and Plasmid DNA Manufacturing Players Revenue Ranking (2023)
2.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue by Company (2019-2024)
2.3 Key Companies Viral Vectors and Plasmid DNA Manufacturing Manufacturing Base Distribution and Headquarters
2.4 Key Companies Viral Vectors and Plasmid DNA Manufacturing Product Offered
2.5 Key Companies Time to Begin Mass Production of Viral Vectors and Plasmid DNA Manufacturing
2.6 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Competitive Analysis
2.6.1 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Viral Vectors and Plasmid DNA Manufacturing Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vectors and Plasmid DNA Manufacturing as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Plasmid DNA
3.1.2 Viral Vectors
3.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type
3.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value, by Type (2019-2030)
3.2.3 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Cancers
4.1.2 Inherited Disorders
4.1.3 Viral Infections
4.1.4 Others
4.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application
4.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value, by Application (2019-2030)
4.2.3 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region
5.1.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2019-2024)
5.1.3 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2025-2030)
5.1.4 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2019-2030
5.2.2 North America Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2019-2030
5.3.2 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2019-2030
5.4.2 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2019-2030
5.5.2 South America Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2019-2030
5.6.2 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Viral Vectors and Plasmid DNA Manufacturing Sales Value
6.3 United States
6.3.1 United States Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2019-2030
6.3.2 United States Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2019-2030
6.4.2 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2019-2030
6.5.2 China Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2023 VS 2030
6.5.3 China Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2019-2030
6.6.2 Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2019-2030
6.7.2 South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2019-2030
6.8.2 Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2019-2030
6.9.2 India Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2023 VS 2030
6.9.3 India Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 BioReliance
7.1.1 BioReliance Profile
7.1.2 BioReliance Main Business
7.1.3 BioReliance Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.1.4 BioReliance Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.1.5 BioReliance Recent Developments
7.2 Cobra Biologics
7.2.1 Cobra Biologics Profile
7.2.2 Cobra Biologics Main Business
7.2.3 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.2.4 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.2.5 Cobra Biologics Recent Developments
7.3 Oxford BioMedica
7.3.1 Oxford BioMedica Profile
7.3.2 Oxford BioMedica Main Business
7.3.3 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.3.4 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.3.5 UniQure Recent Developments
7.4 UniQure
7.4.1 UniQure Profile
7.4.2 UniQure Main Business
7.4.3 UniQure Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.4.4 UniQure Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.4.5 UniQure Recent Developments
7.5 FinVector
7.5.1 FinVector Profile
7.5.2 FinVector Main Business
7.5.3 FinVector Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.5.4 FinVector Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.5.5 FinVector Recent Developments
7.6 MolMed
7.6.1 MolMed Profile
7.6.2 MolMed Main Business
7.6.3 MolMed Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.6.4 MolMed Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.6.5 MolMed Recent Developments
7.7 MassBiologics
7.7.1 MassBiologics Profile
7.7.2 MassBiologics Main Business
7.7.3 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.7.4 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.7.5 MassBiologics Recent Developments
7.8 Richter-Helm
7.8.1 Richter-Helm Profile
7.8.2 Richter-Helm Main Business
7.8.3 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.8.4 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.8.5 Richter-Helm Recent Developments
7.9 FUJIFILM Diosynth Biotechnologies
7.9.1 FUJIFILM Diosynth Biotechnologies Profile
7.9.2 FUJIFILM Diosynth Biotechnologies Main Business
7.9.3 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.9.4 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
7.10 Lonza
7.10.1 Lonza Profile
7.10.2 Lonza Main Business
7.10.3 Lonza Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.10.4 Lonza Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.10.5 Lonza Recent Developments
7.11 Aldevron
7.11.1 Aldevron Profile
7.11.2 Aldevron Main Business
7.11.3 Aldevron Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.11.4 Aldevron Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.11.5 Aldevron Recent Developments
7.12 Eurogentec
7.12.1 Eurogentec Profile
7.12.2 Eurogentec Main Business
7.12.3 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.12.4 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.12.5 Eurogentec Recent Developments
7.13 Cell and Gene Therapy Catapult
7.13.1 Cell and Gene Therapy Catapult Profile
7.13.2 Cell and Gene Therapy Catapult Main Business
7.13.3 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.13.4 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.13.5 Cell and Gene Therapy Catapult Recent Developments
7.14 Biovian
7.14.1 Biovian Profile
7.14.2 Biovian Main Business
7.14.3 Biovian Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.14.4 Biovian Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.14.5 Biovian Recent Developments
7.15 Thermo Fisher Scientific (Brammer Bio)
7.15.1 Thermo Fisher Scientific (Brammer Bio) Profile
7.15.2 Thermo Fisher Scientific (Brammer Bio) Main Business
7.15.3 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.15.4 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.15.5 Thermo Fisher Scientific (Brammer Bio) Recent Developments
7.16 VGXI
7.16.1 VGXI Profile
7.16.2 VGXI Main Business
7.16.3 VGXI Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.16.4 VGXI Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.16.5 VGXI Recent Developments
7.17 PlasmidFactory
7.17.1 PlasmidFactory Profile
7.17.2 PlasmidFactory Main Business
7.17.3 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
7.17.4 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2019-2024)
7.17.5 PlasmidFactory Recent Developments
8 Industry Chain Analysis
8.1 Viral Vectors and Plasmid DNA Manufacturing Industrial Chain
8.2 Viral Vectors and Plasmid DNA Manufacturing Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Viral Vectors and Plasmid DNA Manufacturing Sales Model
8.5.2 Sales Channel
8.5.3 Viral Vectors and Plasmid DNA Manufacturing Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

BioReliance
Cobra Biologics
Oxford BioMedica
UniQure
FinVector
MolMed
MassBiologics
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Lonza
Aldevron
Eurogentec
Cell and Gene Therapy Catapult
Biovian
Thermo Fisher Scientific (Brammer Bio)
VGXI
PlasmidFactory

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.